ZPDH:XETRA:XETRA-SPDR S&P U.S. Health Care Select Sector UCITS (EUR)

ETF | Others |

Last Closing

USD 43.1

Change

-0.17 (-0.39)%

Market Cap

USD 0.40B

Volume

3.45K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-10 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+0.16 (+0.29%)

USD 445.28B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

N/A

USD 191.96B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

-0.03 (-0.10%)

USD 177.46B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.09 (+0.30%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.25 (+0.98%)

USD 157.79B
JARI:XETRA Amundi Index Solutions - Amund..

+0.35 (+0.75%)

USD 102.61B
8R80:XETRA Amundi Index Solutions - Amund..

+0.74 (+0.53%)

USD 98.84B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+0.18 (+0.35%)

USD 85.64B
EUNL:XETRA iShares Core MSCI World UCITS ..

+0.68 (+0.63%)

USD 84.07B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+3.84 (+0.62%)

USD 80.38B

ETFs Containing ZPDH:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.05% 77% C+ 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.05% 77% C+ 73% C
Trailing 12 Months  
Capital Gain 7.35% 36% F 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.35% 34% F 38% F
Trailing 5 Years  
Capital Gain 57.50% 75% C 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 57.50% 73% C 73% C
Average Annual (5 Year Horizon)  
Capital Gain 12.71% 73% C 72% C
Dividend Return 12.71% 73% C 71% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.70% 60% D- 68% D+
Risk Adjusted Return 118.84% 97% N/A 97% N/A
Market Capitalization 0.40B 61% D- 54% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike